Rachel B. Slayton

The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)

The economic impact of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) remains unclear. We developed an economic simulation model to quantify the costs associated with CA-MRSA infection from the societal and third-party payer perspectives. A single CA-MRSA case costs third-party payers

Outbreak of Shiga Toxin-Producing Escherichia coli (STEC) O157:H7 Associated with Romaine Lettuce Consumption, 2011

2277-

The economic value of a visceral leishmaniasis vaccine in Bihar State, India

3200 and society

Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger

7070-

Removing the regional level from the Niger vaccine supply chain

20 489, depending on patient age. In the United States (US), CA-MRSA imposes an annual burden of

The Potential Trajectory of Carbapenem-Resistant Enterobacteriaceae, an Emerging Threat to Health-Care Facilities, and the Impact of the Centers for Disease Control and Prevention Toolkit

478 million to 2.2 billion on third-party payers and

Vaccination for typhoid fever in Sub-Saharan Africa

1.4-13.8 billion on society, depending on the CA-MRSA definitions and incidences. The US jail system and Army may be experiencing annual total costs of

How Influenza Vaccination Policy May affect Vaccine Logistics

7-11 million (

Household Water Treatment Uptake during a Public Health Response to a Large Typhoid Fever Outbreak in Harare, Zimbabwe

6-10 million direct medical costs) and

The cost-benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship program.

15-36 million (